Sarepta Therapeutics (SRPT) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Sarepta Therapeutics (SRPT) PT Raised to $96 at H.C. Wainwright
May 7, 2018 8:17 AM EDTH.C. Wainwright raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $96.00 (from $90.00) while maintaining a Buy rating following the company's 1Q. During its 1Q18 corporate update, Sarepta also disclosed an exclusive collaboration and investment in Myonexus Therapeutics.
The alliance,... More
Sarepta Therapeutics (SRPT) PT Raised to $109 at Needham & Company
May 7, 2018 6:20 AM EDTNeedham & Company raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $109.00 (from $75.00) while maintaining a Buy rating.
Analsyt Chad Messer commented, "Sarepta reported in line 1Q:18 Exondys revenues of $64.6M. Exondys received a negative trend vote in the EU, for which Sarepta... More
Sarepta Therapeutics (SRPT) PT Raised to $98 at RBC Capital
May 4, 2018 8:50 AM EDTRBC Capital raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $98.00 (from $91.00) while maintaining an Outperform rating.
Analyst Rick Bienkowski commented, "On the back of solid 1Q Exondys 51 sales reaffirming confidence in 2018 revenues and future DMD franchise growth, and increasing enthusiasm into June's... More
